en · de · es · fr · pt
aod-9604-notes.peptides6908.com › Data › Research And Regulatory Status — Common Mistakes

Research And Regulatory Status — Common Mistakes

By Editorial Desk · published 2026-03-31 · last reviewed 2026-05-10 · Data

If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-05-10. Numbers and descriptions here follow the published literature rather than marketing material.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Mechanism and Regulatory Status

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Related pages on this site

Mechanism And Metabolic Effects

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.

Background and Molecular Identity

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

Reference notes

In February 2011, the European Commission's Committee for Medicinal Products for Human Use approved the product for the treatment of Dupuytren's contracture in adults with a palpable cord by 'properly trained' doctors. Pfizer was reported to be working with Europe's national medicines regulatory bodies to launch the new treatment, hoping doctors could prescribe the treatment by late 2011. On November 7, 2012, BioSpecifics announced "BioSpecifics Technologies Corp. : Reports Third Quarter 2012 Financial Results". Auxilium's submission of a License Application to the FDA for Xiaflex for the potential treatment of Peyronie's disease, an excess of inelastic collagen causing penile curvature deformity. The FDA approved Xiaflex for the treatment of Peyronie’s disease in December 2013. Following this, Xiapex gained EU approval for the treatment of Peyronie’s disease in February 2015, making it the first and only biologic therapy indicated for the treatment of Peyronie's disease. Auxilium has also reported additional trials for potential use of Xiaflex are underway for the treatment of frozen shoulder, cellulite reductions and both human and canine lipomas. In March 2020, the Swedish manufacturer abruptly withdrew distribution of this drug in Europe for commercial reasons. Collagenase is no longer available on the National Health System except as part of a small clinical trial.

Tocochromanols protect the seed lipids from oxidizing and becoming rancid. The presence of tocochromanols extends seed longevity and promotes successful germination and seedling growth. Gamma-tocopherol dominates in seeds of most plant species, but there are exceptions. For canola, corn and soy bean oils, there is more γ-tocopherol than α-tocopherol, but for safflower, sunflower and olive oils the reverse is true. Of the commonly used food oils, palm oil is unique in that tocotrienol content is higher than tocopherol content. Seed tocochromanols content is also dependent on environmental stressors. In almonds, for example, drought or elevated temperature increase α-tocopherol and γ-tocopherol content of the nuts. Drought increases the tocopherol content of olives, and heat likewise for soybeans. Vitamin E biosynthesis occurs in the plastid and goes through two different pathways: the Shikimate pathway and the Methylerythritol Phosphate pathway (MEP pathway). The Shikimate pathway generates the chromanol ring from the Homogentisic Acid (HGA), and the MEP pathway produces the hydrophobic tail which differs between tocopherol and tocotrienol. The synthesis of the specific tail is dependent on which molecule it originates from. In a tocopherol, its prenyl tail emerges from the geranylgeranyl diphosphate (GGDP) group, while the phytyl tail of a tocotrienol stems from a phytyl diphosphate.

Squadron Leader Iain Roderic Gillespie (2618287), (Retired). Warrant Officer Anthony John Gough, , (N1944467). Corporal (now Acting Sergeant) Alistair Colin Green (B8213475). Warrant Officer Michael John Hatch (M0593513). Squadron Leader Mark William Gardner Hopkins (2625781). Warrant Officer William James Cameron Kearney, , (D1949781). Sergeant Gary Kennedy (L8001367). Sergeant Roy Martin (A8015128). Warrant Officer Brian David Medland (R1949361), (Retired). Corporal (now Acting Sergeant) Kevin John Mulloy (F8201300). Corporal Ian William Partington (T8153337). Squadron Leader Vivienne Alexandra Sim (2797569), (Retired). Warrant Officer Keith Alexander Smith (P8089172). Squadron Leader Steven Glynn Smyth (8025529). Warrant Officer Barry Walch (U4287360). Junior Technician Peter Allan Wildman (D8410829). Squadron Leader Timothy Andrew Wilkinson (5203138). Master Aircrew Alistair John Woolfson (T8018944). Civil Division Kenneth Elliott Ackerley. For services to Physically Handicapped People. Graham Clifford Adams, Storekeeper, Manufacturing Division, Rolls-Royce & Associates plc. For services to the Automobile Industry. William Aitken. For services to the community in Aberdeen. Anne Aldred, Revenue Assistant, Board of Inland Revenue. Richard John Alibone, Senior Professional Technical Officer, Foreign and Commonwealth Office. Lieutenant Commander Peter Douglas Allen, Royal Navy (Retd.), Retired Officer 2, Ministry of Defence. Yashwanti Chandrakant Amlani. For services to Community Relations in Bristol. Ann McCall Amos, Personal Secretary, Ministry of Defence.

== Early political career (2007-2018) == Bhutto Zardari was appointed as the Chairman of the Pakistan Peoples Party (PPP), on 30 December 2007 at the age of 19, following the assassination of his mother in Rawalpindi earlier that month during a political rally. On this occasion, he recalled his martyred mother, "My mother always said that democracy is the best revenge". In the 2018 Pakistani general election, the PPP, under the leadership of Bilawal Zardari, emerged as the largest party in Sindh and third largest party of Pakistan. The party won 43 seats in the National Assembly, nine more seats than in the 2013 general election. Bhutto Zardari, contested from NA-246 Karachi West-III, Malakand NA-8, as well as NA-200 Larkana. He won from Larkana with 84,426 votes, having lost from two of the other constituencies to candidates for the Imran Khan-founded Pakistan Tehreek-e-Insaf (PTI). Bhutto Zardari claimed that rigging took place before and after the general election, adding that across Pakistan polling agents were expelled from the polling stations and demanding a probe into rigging allegations.

Sources: en.wikipedia.org

Reference notes

== Biosynthesis == Felinine synthesis starts in the liver through a condensation reaction of glutathione and isopentenyl pyrophosphate to form 3-methylbutanolglutathionine (3-MBG). Then, kidney epithelia tissue secretes γ-glutamyl transpeptidase (γ-GTP). γ-GTP converts 3-MBG to 3-methylbutanol-cysteinylglycine (MBCG). Next, a majority of MBCG is hydrolyzed to felinine and glycine by carboxylesterase 5A, or cauxin. Cauxin specifically works by hydrolyzing the dipeptide (felinylglycine) in MBCG to increase the concentration of urinary felinine. The leftover MBCG is converted to felinine and secreted into the cells where it is acetylated and transported to fecal material. Therefore, high concentration of felinine is present in urine while a minor concentration of N-acetylfelinine is present in cat excrement.

=== Discovery of catalytic RNA (ribozymes) === An experimental system was developed in which an intron-containing rRNA precursor from the nucleus of the ciliated protozoan Tetrahymena could be spliced in vitro. Subsequent biochemical analysis shows that this group I intron was self-splicing; that is, the precursor RNA is capable of carrying out the complete splicing reaction in the absence of proteins. In separate work, the RNA component of the bacterial enzyme ribonuclease P (a ribonucleoprotein complex) was shown to catalyze its tRNA-processing reaction in the absence of proteins. These experiments represented landmarks in RNA biology, since they revealed that RNA could play an active role in cellular processes, by catalyzing specific biochemical reactions. Before these discoveries, it was believed that biological catalysis was solely the realm of protein enzymes.

Major subranges of the Eastern Front include the Black Mountains, Great Craggy Mountains, and Great Balsam Mountains, and its chief summits include Grandfather Mountain 5,964 ft (1,818 m) near the Tennessee-North Carolina border, Mount Mitchell 6,684 ft (2,037 m) in the Blacks, and Black Balsam Knob 6,214 ft (1,894 m) and Cold Mountain 6,030 ft (1,840 m) in the Great Balsams. The Western Blue Ridge Front is subdivided into the Unaka Range, the Bald Mountains, the Great Smoky Mountains, and the Unicoi Mountains, and its major peaks include Roan Mountain 6,285 ft (1,916 m) in the Unakas, Big Bald 5,516 ft (1,681 m) and Max Patch 4,616 ft (1,407 m) in the Bald Mountains, Kuwohi 6,643 ft (2,025 m), Mount Le Conte 6,593 feet (2,010 m), and Mount Guyot 6,621 ft (2,018 m) in the Great Smokies, and Big Frog Mountain 4,224 ft (1,287 m) near the Tennessee-Georgia-North Carolina border. Prominent summits in the cross ridges include Waterrock Knob (6,292 ft (1,918 m)) in the Plott Balsams. Across northern Georgia, numerous peaks exceed 4,000 ft (1,200 m), including Brasstown Bald, the state's highest, at 4,784-and-4,696 ft (1,458-and-1,431 m) Rabun Bald. In north-central Alabama, Mount Cheaha rises prominently to 1,445 feet (440 m) over its surroundings, as part of the southernmost spur of the Blue Ridge Mountains.

=== Chemical intermediate === Glycerol is used to produce a variety of useful derivatives. Nitration gives nitroglycerin, an essential ingredient of various explosives such as dynamite, gelignite, and propellants like cordite. Nitroglycerin under the name glyceryl trinitrate (GTN) is commonly used to relieve angina pectoris, taken in the form of sublingual tablets, patches, or as an aerosol spray. Trifunctional polyether polyols are produced from glycerol and propylene oxide. Oxidation of glycerol affords mesoxalic acid. Dehydrating glycerol affords hydroxyacetone. Chlorination of glycerol gives the 1-chloropropane-2,3-diol:

is the distance traveled by the liquid. More extensive models account for paper tortuosity, pore radius, and paper deformation. Once the medium is fully wetted, subsequent flow is laminar and follows Darcy's law. The average velocity of fluid flow is generalized as,

Sources: en.wikipedia.org

Reference notes

Jesse Bloom (Jay Duplass) is an independent billionaire investor who profited heavily from the COVID-19 pandemic. He owns the hedge fund Crotona Capital and becomes a mentor and tenuous ally to Harper, who admires his maverick investment philosophy. In series 2, Harper meets Jesse while living in a hotel and working remotely, and begins courting him as a Pierpoint client. Jesse first becomes central to Pierpoint’s business through a $3.3 billion block trade in healthcare startup Rican: when anchor investor Felim Bichan withdraws after Harper misses a client meeting, Harper sells the shares to Jesse at the last moment. Acting on Harper’s advice and against Eric’s instructions, Jesse later buys out FutureDawn Partners’ stake in Rican, securing a controlling interest that Eric had promised to Felim. Jesse employs Gus Sackey to tutor his estranged son Leo, and Gus and Leo begin a relationship. Later, on Harper’s recommendation, Jesse enters a short position in brick-and-mortar pharmacy chain FastAide, routed through another bank rather than Pierpoint; when the trade turns against him, he visits Pierpoint to confront Harper, and later abandons a scheduled public speaking appearance after receiving a call from Leo. When Gus leaks to Harper that the government is allowing Amazon to acquire FastAide, Harper alerts Jesse. Jesse then goes on television to publicly criticize the acquisition, reviving regulatory scrutiny and protecting his short position. Gus is fired for the leak but later hired by Jesse as an assistant.

== See also == Baby Friendly Hospital Initiative Breastfeeding promotion Breastfeeding contraindications Haberman Feeder Infant formula International Code of Marketing of Breast-milk Substitutes List of bottle types, brands and companies

Although most gluconeogenesis occurs in the liver, the relative contribution of gluconeogenesis by the kidney is increased in diabetes and prolonged fasting. The gluconeogenesis pathway is highly endergonic until it is coupled to the hydrolysis of ATP or guanosine triphosphate (GTP), effectively making the process exergonic. For example, the pathway leading from pyruvate to glucose-6-phosphate requires 4 molecules of ATP and 2 molecules of GTP to proceed spontaneously. These ATPs are supplied from fatty acid catabolism via beta oxidation.

=== Health care === Wittman opposes the Affordable Care Act and has voted to repeal it. He said that Congress should not merely be "anti-Obamacare" and that congressional Republicans are ready to provide alternatives if it is deemed unconstitutional. In 2017, he voted for the American Health Care Act, which would have repealed and replaced the ACA.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

Network